Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487465 | 0.80 | TAAR1 (0.73) | SLC6A2TAAR1CYP2D6LMNASMN1; SMN2 | |
| SCHEMBL516033 | 0.80 | TAAR1 (0.73) | SLC6A2TAAR1CYP2D6LMNASMN1; SMN2 | |
| SCHEMBL27795386 | 0.80 | TAAR1 (0.58) | SLC6A2TAAR1CYP2D6LMNASMN1; SMN2 | |
| Phentermine SCHEMBL10392295 | 0.80 | SLC6A2 (1.00) | SLC6A2TAAR1CYP2D6LMNASMN1; SMN2 | |
| SCHEMBL2313943 | 0.80 | SLC6A2 (0.58) | SLC6A2TAAR1CYP2D6LMNASMN1; SMN2 | |
| SCHEMBL27999855 | 0.80 | SLC6A2 (0.58) | SLC6A2TAAR1CYP2D6LMNASMN1; SMN2 | |
| Phentermine SCHEMBL26615 | 0.80 | SLC6A2 (1.00) | SLC6A2TAAR1CYP2D6LMNASMN1; SMN2 | |
| Phentermine SCHEMBL28729624 | 0.78 | SLC6A2 (0.95) | SLC6A2TAAR1CYP2D6LMNASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL29011215 | 0.78 | SLC6A2 (0.56) | SLC6A2TAAR1CYP2D6LMNASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL2477835 | 0.78 | SLC6A2 (0.70) | SLC6A2TAAR1CYP2D6LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| CN-101056631-A | Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction | ESTEVE LABOR DR (ES) | 2007-10-17 | — | — | CN | claimed |
| CN-101031291-A | Compound containing methanol and composition containing at least one nsaid active substance | ESTEVE LABOR DR (ES) | 2007-09-05 | — | — | CN | claimed |
| CN-1976722-A | Active substance combination | ESTEVE LABOR DR (ES) | 2007-06-06 | — | — | CN | claimed |
| EP-1786420-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF CENTRAL NEUROPATHIC PAIN | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-1786419-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS (IN PARTICULAR CIZOLIRTIN CITRATE) FOR THE TREATMENT OF OPIOID ADDICTION | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-04-19 | — | — | US | claimed |
| US-20070082893-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-12 | — | — | US | claimed |
| EP-1755678-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-28 | — | — | EP | claimed |
| EP-1746986-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-31 | — | — | EP | claimed |
| EP-1690537-A1 | Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-16 | — | — | EP | claimed |
| EP-1642577-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain | Laboratorios del Dr. Esteve S.A. (ES) | 2006-04-05 | — | — | EP | claimed |
| WO-2006027221-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS (IN PARTICULAR CIZOLIRTIN CITRATE) FOR THE TREATMENT OF OPIOID ADDICTION | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2006-03-16 | — | — | WO | claimed |
| WO-2006027226-A1 | DERIVATIVES OF ARYL(OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF CENTRAL NEUROPATHIC PAIN | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2006-03-16 | — | — | WO | claimed |
| EP-1632227-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction | Laboratorios del Dr. Esteve S.A. (ES) | 2006-03-08 | — | — | EP | claimed |
| US-20060040924-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic | LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-02-23 | — | — | US | claimed |
| WO-2005097192-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-20 | — | — | WO | claimed |
| WO-2005097099-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-20 | — | — | WO | claimed |
| EP-1584335-A2 | Active substance combination comprising a carbinol composition and an opioid | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-12 | — | — | EP | claimed |
| US-20050222136-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | PTGS1, PTGS2, PTGES2 | SLC6A2 1741/4885TAAR1 1697/4885CYP2D6 404/4885 |
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | CNR2, CNR1, HCRTR2 | SLC6A2 299/4885TAAR1 13/4885CYP2D6 187/4885 |
| US-20050222136-A1 | Active substance combination | PTGS1, MMP8, TACR1 | SLC6A2 690/4885TAAR1 620/4885CYP2D6 636/4885 |
| US-20060040924-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic | SLC10A2, FABP2, FANCI | SLC6A2 1644/4885TAAR1 1358/4885CYP2D6 595/4885 |
| US-20070082893-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | SLC6A2 140/4885TAAR1 147/4885CYP2D6 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.